In June, the CDC recommended that individuals aged 6 months and older should receive both a Covid-19 shot and a flu shot this year.
The FDA is likely to approve new COVID-19 vaccines that are effective against the latest virus strains. This news comes from two sources familiar with the situation. The approval is expected to happen this week.
This development comes as the nation grapples with its largest summer surge in two years.
The FDA is likely to approve new mRNA vaccines from Moderna and Pfizer/BioNTech to fight a strain called KP.2. Anonymous sources, who want to stay unidentified, shared this information because the timing details are confidential.
It's unclear whether the FDA will also give the green light to Novavax's updated vaccine, which targets the JN.1 strain.
Dr. Michael Osterholm, from the University of Minnesota, says now is the time to get vaccinated. He made this statement in an interview with CNN. Dr. Osterholm got a booster shot from last season's vaccine to boost his immunity against the fast-spreading virus. He did this because new vaccines may not be available soon and there is uncertainty about their effectiveness. He plans to wait four months for the new vaccine, following the advice of health officials.
In June, the CDC advised everyone 6 months and older to get a new COVID-19 vaccine and a flu shot this year.
Pfizer and Moderna have said they have plenty of the new Covid vaccines and are prepared to give them out once they are approved. Moderna's spokesperson said that the vaccine is expected to be available in stores shortly after the FDA's approval.
Novavax's vaccine, developed using protein technology, takes longer to manufacture than mRNA vaccines. Executives from Novavax mentioned during a recent investor conference call that they anticipate their updated vaccine to be in storage this month and ready for distribution after approval. A Novavax spokesperson did not respond to a request for comment on Friday.
An FDA spokesperson said that the agency cannot disclose the specifics of the timing for product applications but assured that it is dedicated to swiftly authorizing or approving updated COVID-19 vaccines to ensure they are available this fall.
Comments
Post a Comment